A Safety, Tolerability, PK, and PD Study of Once Weekly ISIS-FGFR4RX SC in Obese Patients

NCT02476019 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

13

Enrollment

INDUSTRY

Sponsor class

Conditions

Obesity

Interventions

DRUG: ISIS-FGFR4RX
DRUG: Placebo

Sponsor

Ionis Pharmaceuticals, Inc.